Symbols / ATNM $1.30 -2.99% Actinium Pharmaceuticals, Inc.
ATNM Chart
Stock Fundamentals
|
|
|
|
|
|
About
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Ratings
Current target
$1.30
Low
$2.00
High
$9.00
Mean
$5.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-31 | reit | Stephens & Co. | Overweight → Overweight | $5 |
| 2025-06-24 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-05-12 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-04-28 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-27 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-25 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-11 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-11-19 | reit | Stephens & Co. | Overweight → Overweight | $5 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-08-06 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-08-06 | main | Maxim Group | Buy → Buy | $5 |
| 2024-07-26 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2024-06-17 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2024-05-21 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2024-05-14 | init | Stephens & Co. | — → Overweight | $25 |
| 2024-05-02 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2024-04-30 | reit | Cantor Fitzgerald | Overweight → Overweight | $21 |
- Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization - PR Newswire Wed, 06 May 2026 12
- ATNM Should I Buy - Intellectia AI Fri, 08 May 2026 07
- SLS vs ATNM: Which cancer stock has bigger upside ahead of fresh data reveal? - MSN Mon, 11 May 2026 01
- SLS Vs ATNM: Which Cancer Stock Has Bigger Upside Ahead Of Fresh Data Reveal? - Stocktwits Mon, 20 Apr 2026 09
- Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? - Yahoo Finance Mon, 22 Dec 2025 08
- Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting - PR Newswire Mon, 06 Apr 2026 07
- [10-Q] Actinium Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan Fri, 08 May 2026 21
- Actinium Pharmaceuticals presents preclinical data for ATNM-400 - Investing.com Wed, 22 Apr 2026 07
- TradingKey - TradingKey Mon, 11 May 2026 15
- Actinium (ATNM) Stock: Is It a Strong Buy? (+4.00%) 2026-04-18 - AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai Sat, 18 Apr 2026 12
- The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet - TMX Newsfile Mon, 17 Nov 2025 08
- Why Is Actinium Pharmaceuticals Stock Rising Today? - Stocktwits Fri, 12 Dec 2025 08
- MSN Money - MSN Fri, 08 May 2026 20
- Why is Actinium Pharmaceuticals stock rising today? - MSN Fri, 12 Dec 2025 15
- MSN Money - MSN Wed, 22 Apr 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.09
|
0.00
-100.00%
|
0.08
-92.14%
|
1.03
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
36.34
-13.73%
|
42.12
-19.00%
|
52.00
+48.01%
|
35.13
|
| Research And Development |
|
21.12
-29.69%
|
30.05
-22.30%
|
38.67
+67.15%
|
23.14
|
| Selling General And Administration |
|
15.21
+25.98%
|
12.08
-9.41%
|
13.33
+11.10%
|
12.00
|
| General And Administrative Expense |
|
15.21
+25.98%
|
12.08
-9.41%
|
13.33
+11.10%
|
12.00
|
| Other Gand A |
|
15.21
+25.98%
|
12.08
-9.41%
|
13.33
+11.10%
|
12.00
|
| Total Expenses |
|
36.34
-13.73%
|
42.12
-19.00%
|
52.00
+48.01%
|
35.13
|
| Operating Income |
|
-36.25
+13.95%
|
-42.12
+18.87%
|
-51.92
-52.24%
|
-34.10
|
| Total Operating Income As Reported |
|
-36.25
+13.95%
|
-42.12
+18.87%
|
-51.92
-52.24%
|
-34.10
|
| EBITDA |
|
-35.43
+14.24%
|
-41.31
+19.21%
|
-51.13
-53.06%
|
-33.41
|
| Normalized EBITDA |
|
-35.43
+14.24%
|
-41.31
+19.21%
|
-51.13
-53.06%
|
-33.41
|
| Reconciled Depreciation |
|
0.82
+1.23%
|
0.81
+2.66%
|
0.79
+13.02%
|
0.70
|
| EBIT |
|
-36.25
+13.95%
|
-42.12
+18.87%
|
-51.92
-52.24%
|
-34.10
|
| Net Income |
|
-33.89
+11.39%
|
-38.24
+21.66%
|
-48.82
-47.86%
|
-33.02
|
| Pretax Income |
|
-33.89
+11.39%
|
-38.24
+21.66%
|
-48.82
-47.86%
|
-33.02
|
| Net Non Operating Interest Income Expense |
|
2.36
-39.14%
|
3.88
+25.02%
|
3.10
+185.37%
|
1.09
|
| Net Interest Income |
|
2.36
-39.14%
|
3.88
+25.02%
|
3.10
+185.37%
|
1.09
|
| Interest Income Non Operating |
|
2.36
-39.14%
|
3.88
+25.02%
|
3.10
+185.37%
|
1.09
|
| Interest Income |
|
2.36
-39.14%
|
3.88
+25.02%
|
3.10
+185.37%
|
1.09
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-33.89
+11.39%
|
-38.24
+21.66%
|
-48.82
-47.86%
|
-33.02
|
| Net Income From Continuing Operation Net Minority Interest |
|
-33.89
+11.39%
|
-38.24
+21.66%
|
-48.82
-47.86%
|
-33.02
|
| Net Income From Continuing And Discontinued Operation |
|
-33.89
+11.39%
|
-38.24
+21.66%
|
-48.82
-47.86%
|
-33.02
|
| Net Income Continuous Operations |
|
-33.89
+11.39%
|
-38.24
+21.66%
|
-48.82
-47.86%
|
-33.02
|
| Normalized Income |
|
-33.89
+11.39%
|
-38.24
+21.66%
|
-48.82
-47.86%
|
-33.02
|
| Net Income Common Stockholders |
|
-33.89
+11.39%
|
-38.24
+21.66%
|
-48.82
-47.86%
|
-33.02
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
—
|
| Diluted EPS |
|
-1.09
+14.17%
|
-1.27
+30.60%
|
-1.83
-33.58%
|
-1.37
|
| Basic EPS |
|
-1.09
+14.17%
|
-1.27
+30.60%
|
-1.83
-33.58%
|
-1.37
|
| Basic Average Shares |
|
31.20
+3.74%
|
30.07
+13.03%
|
26.60
+10.20%
|
24.14
|
| Diluted Average Shares |
|
31.20
+3.74%
|
30.07
+13.03%
|
26.60
+10.20%
|
24.14
|
| Diluted NI Availto Com Stockholders |
|
-33.89
+11.39%
|
-38.24
+21.66%
|
-48.82
-47.86%
|
-33.02
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
51.77
-32.67%
|
76.90
-5.58%
|
81.44
-28.68%
|
114.19
|
| Current Assets |
|
49.38
-33.72%
|
74.51
-4.80%
|
78.26
-29.46%
|
110.94
|
| Cash Cash Equivalents And Short Term Investments |
|
48.00
-34.16%
|
72.90
-4.92%
|
76.68
-29.60%
|
108.91
|
| Cash And Cash Equivalents |
|
48.00
-34.16%
|
72.90
-4.92%
|
76.68
-29.60%
|
108.91
|
| Prepaid Assets |
|
1.22
-2.41%
|
1.25
-8.46%
|
1.36
-13.43%
|
1.57
|
| Restricted Cash |
|
—
|
—
|
0.00
-100.00%
|
0.40
|
| Other Current Assets |
|
0.17
-52.94%
|
0.36
+57.96%
|
0.23
+247.69%
|
0.07
|
| Total Non Current Assets |
|
2.39
+0.04%
|
2.39
-24.80%
|
3.18
-2.09%
|
3.25
|
| Net PPE |
|
2.06
-0.48%
|
2.07
-27.88%
|
2.87
-2.68%
|
2.95
|
| Gross PPE |
|
3.12
+5.51%
|
2.96
-16.92%
|
3.56
+3.73%
|
3.44
|
| Accumulated Depreciation |
|
-1.06
-19.42%
|
-0.89
-28.39%
|
-0.69
-42.51%
|
-0.49
|
| Machinery Furniture Equipment |
|
0.44
+0.00%
|
0.44
+0.00%
|
0.44
+39.05%
|
0.32
|
| Construction In Progress |
|
0.10
|
0.00
|
—
|
—
|
| Other Properties |
|
2.58
+2.34%
|
2.52
-19.30%
|
3.12
+0.16%
|
3.12
|
| Non Current Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Non Current Assets |
|
0.34
+3.40%
|
0.32
+3.51%
|
0.31
+3.64%
|
0.30
|
| Total Liabilities Net Minority Interest |
|
43.94
-0.45%
|
44.14
-2.05%
|
45.07
-5.54%
|
47.71
|
| Current Liabilities |
|
7.97
-2.20%
|
8.15
-4.07%
|
8.49
-20.08%
|
10.63
|
| Payables And Accrued Expenses |
|
7.25
-4.24%
|
7.57
-4.84%
|
7.95
-21.49%
|
10.13
|
| Current Debt And Capital Lease Obligation |
|
0.72
+24.48%
|
0.58
+7.21%
|
0.54
+8.63%
|
0.50
|
| Current Capital Lease Obligation |
|
0.72
+24.48%
|
0.58
+7.21%
|
0.54
+8.63%
|
0.50
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
0.00
|
| Current Deferred Revenue |
|
—
|
—
|
—
|
0.00
|
| Other Current Liabilities |
|
—
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
35.97
-0.06%
|
35.99
-1.58%
|
36.57
-1.38%
|
37.08
|
| Long Term Debt And Capital Lease Obligation |
|
0.97
-2.11%
|
0.99
-36.83%
|
1.57
-24.53%
|
2.08
|
| Long Term Capital Lease Obligation |
|
0.97
-2.11%
|
0.99
-36.83%
|
1.57
-24.53%
|
2.08
|
| Non Current Deferred Liabilities |
|
35.00
+0.00%
|
35.00
+0.00%
|
35.00
+0.00%
|
35.00
|
| Non Current Deferred Revenue |
|
35.00
+0.00%
|
35.00
+0.00%
|
35.00
+0.00%
|
35.00
|
| Stockholders Equity |
|
7.83
-76.09%
|
32.76
-9.95%
|
36.38
-45.28%
|
66.48
|
| Common Stock Equity |
|
7.83
-76.09%
|
32.76
-9.95%
|
36.38
-45.28%
|
66.48
|
| Capital Stock |
|
0.03
+0.00%
|
0.03
+10.71%
|
0.03
+7.69%
|
0.03
|
| Common Stock |
|
0.03
+0.00%
|
0.03
+10.71%
|
0.03
+7.69%
|
0.03
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
31.20
+0.00%
|
31.20
+12.89%
|
27.63
+7.63%
|
25.67
|
| Ordinary Shares Number |
|
31.20
+0.00%
|
31.20
+12.89%
|
27.63
+7.63%
|
25.67
|
| Additional Paid In Capital |
|
417.54
+2.20%
|
408.55
+9.26%
|
373.93
+5.27%
|
355.22
|
| Retained Earnings |
|
-409.71
-9.02%
|
-375.83
-11.33%
|
-337.58
-16.91%
|
-288.76
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.02
|
0.00
|
—
|
—
|
| Other Equity Adjustments |
|
-0.02
|
—
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
7.83
-76.09%
|
32.76
-9.95%
|
36.38
-45.28%
|
66.48
|
| Total Capitalization |
|
7.83
-76.09%
|
32.76
-9.95%
|
36.38
-45.28%
|
66.48
|
| Working Capital |
|
41.41
-37.59%
|
66.36
-4.89%
|
69.77
-30.45%
|
100.31
|
| Invested Capital |
|
7.83
-76.09%
|
32.76
-9.95%
|
36.38
-45.28%
|
66.48
|
| Total Debt |
|
1.69
+7.69%
|
1.57
-25.56%
|
2.11
-18.13%
|
2.58
|
| Capital Lease Obligations |
|
1.69
+7.69%
|
1.57
-25.56%
|
2.11
-18.13%
|
2.58
|
| Net Tangible Assets |
|
7.83
-76.09%
|
32.76
-9.95%
|
36.38
-45.28%
|
66.48
|
| Tangible Book Value |
|
7.83
-76.09%
|
32.76
-9.95%
|
36.38
-45.28%
|
66.48
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-24.58
+25.68%
|
-33.07
+30.13%
|
-47.34
-647.61%
|
8.64
|
| Cash Flow From Continuing Operating Activities |
|
-24.58
+25.68%
|
-33.07
+30.13%
|
-47.34
-647.61%
|
8.64
|
| Net Income From Continuing Operations |
|
-33.89
+11.39%
|
-38.24
+21.66%
|
-48.82
-47.86%
|
-33.02
|
| Depreciation Amortization Depletion |
|
0.82
+1.23%
|
0.81
+2.66%
|
0.79
+13.02%
|
0.70
|
| Depreciation |
|
0.82
+1.23%
|
0.81
+2.66%
|
0.79
|
—
|
| Depreciation And Amortization |
|
0.82
+1.23%
|
0.81
+2.66%
|
0.79
+13.02%
|
0.70
|
| Stock Based Compensation |
|
9.19
+73.66%
|
5.29
+37.74%
|
3.84
+37.46%
|
2.79
|
| Change In Working Capital |
|
-0.70
+24.46%
|
-0.93
+70.40%
|
-3.15
-108.25%
|
38.17
|
| Change In Prepaid Assets |
|
0.22
+1560.00%
|
-0.01
-130.61%
|
0.05
+131.01%
|
-0.16
|
| Change In Payables And Accrued Expense |
|
-0.35
+10.59%
|
-0.39
+82.22%
|
-2.18
-147.38%
|
4.59
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
34.00
|
| Change In Other Current Assets |
|
—
|
0.00
+100.00%
|
-0.53
|
0.00
|
| Change In Other Current Liabilities |
|
-0.58
-8.87%
|
-0.53
-7.29%
|
-0.49
-81.62%
|
-0.27
|
| Investing Cash Flow |
|
-0.10
-845.45%
|
-0.01
+92.81%
|
-0.15
+58.20%
|
-0.37
|
| Cash Flow From Continuing Investing Activities |
|
-0.10
-845.45%
|
-0.01
+92.81%
|
-0.15
+58.20%
|
-0.37
|
| Net PPE Purchase And Sale |
|
-0.10
-845.45%
|
-0.01
+92.81%
|
-0.15
+58.20%
|
-0.37
|
| Purchase Of PPE |
|
-0.10
-845.45%
|
-0.01
+92.81%
|
-0.15
+58.20%
|
-0.37
|
| Capital Expenditure |
|
-0.10
-845.45%
|
-0.01
+92.81%
|
-0.15
+58.20%
|
-0.37
|
| Financing Cash Flow |
|
-0.22
-100.74%
|
29.32
+97.18%
|
14.87
-35.65%
|
23.11
|
| Cash Flow From Continuing Financing Activities |
|
-0.22
-100.74%
|
29.32
+97.18%
|
14.87
-35.65%
|
23.11
|
| Net Issuance Payments Of Debt |
|
-0.01
-11.11%
|
-0.01
-125.00%
|
-0.00
+91.84%
|
-0.05
|
| Repayment Of Debt |
|
-0.01
-11.11%
|
-0.01
-125.00%
|
-0.00
+91.84%
|
-0.05
|
| Long Term Debt Payments |
|
-0.01
-11.11%
|
-0.01
-125.00%
|
-0.00
+91.84%
|
-0.05
|
| Net Long Term Debt Issuance |
|
-0.01
-11.11%
|
-0.01
-125.00%
|
-0.00
+91.84%
|
-0.05
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
29.25
+100.21%
|
14.61
-36.90%
|
23.16
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
0.07
-71.37%
|
0.26
|
0.00
|
| Net Other Financing Charges |
|
-0.21
|
—
|
—
|
—
|
| Changes In Cash |
|
-24.90
-561.91%
|
-3.76
+88.47%
|
-32.62
-203.92%
|
31.39
|
| Effect Of Exchange Rate Changes |
|
0.01
|
0.00
|
—
|
—
|
| Beginning Cash Position |
|
73.23
-4.89%
|
76.99
-29.76%
|
109.61
+40.13%
|
78.22
|
| End Cash Position |
|
48.33
-34.00%
|
73.23
-4.89%
|
76.99
-29.76%
|
109.61
|
| Free Cash Flow |
|
-24.68
+25.39%
|
-33.08
+30.33%
|
-47.49
-673.67%
|
8.28
|
| Interest Paid Supplemental Data |
|
—
|
0.00
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
—
|
0.00
|
0.00
|
0.00
|
| Common Stock Issuance |
|
0.00
-100.00%
|
29.25
+100.21%
|
14.61
-36.90%
|
23.16
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
29.25
+100.21%
|
14.61
-36.90%
|
23.16
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-05-08 View
- 10-K2026-03-30 View
- 8-K2026-02-13 View
- 8-K2025-11-26 View
- 10-Q2025-11-14 View
- 42025-08-20 View
- 10-Q2025-08-08 View
- 10-Q2025-05-09 View
- 8-K2025-05-09 View
- 42025-04-02 View
- 42025-04-02 View
- 42025-04-02 View
- 42025-04-02 View
- 42025-04-02 View
- 42025-04-02 View
- 42025-04-02 View
- 10-K2025-03-31 View
- 8-K2024-11-27 View
- 10-Q2024-11-14 View
- 42024-11-05 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|